Abstract |
To evaluate whether all-trans-retinoic acid (ATRA) is able to modulate the hemostatic system in patients with solid tumors, we studied patients with locally advanced breast cancer who were enrolled in a Phase Ib study of ATRA +/- Tamoxifen (Tam). In this study, two groups of 15 patients/each were treated for 21 days before operation with ATRA at three doses (15, 45, or 75 mg/m(2)/day on alternate days) given alone (group 1) or in combination with Tam (group 2). One additional group received Tam alone. Plasma samples were evaluated for hypercoagulation markers (FVIIa, F1+2, TAT, D-dimer), fibrinolysis proteins (t-PA, PAI-1), and coagulation inhibitors ( protein C, AT). At baseline, cancer patients had FVIIa, F1+2, TAT, and PAI-1 significantly greater than control subjects. During treatment, in the patients given ATRA alone, hypercoagulation markers appeared unmodified. Instead, subjects given Tam alone had a significant elevation of FVIIa, F1+2, and TAT versus baseline. However, in the ATRA + Tam groups, hypercoagulation markers were decreased compared with Tam alone. These results suggest that in selected conditions, pre-operative ATRA may modulate the hypercoagulable state of breast cancer patients.
|
Authors | Anna Falanga, S Toma, M Marchetti, R Palumbo, P Raffo, R Consonni, S Marziali, G Dastoli, T Barbui |
Journal | American journal of hematology
(Am J Hematol)
Vol. 70
Issue 1
Pg. 9-15
(May 2002)
ISSN: 0361-8609 [Print] United States |
PMID | 11994976
(Publication Type: Clinical Trial, Clinical Trial, Phase I, Controlled Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2002 Wiley-Liss, Inc. |
Chemical References |
- Antineoplastic Agents
- Antineoplastic Agents, Hormonal
- Biomarkers
- Tamoxifen
- Tretinoin
- Tissue Plasminogen Activator
|
Topics |
- Aged
- Antineoplastic Agents
(administration & dosage, therapeutic use)
- Antineoplastic Agents, Hormonal
(administration & dosage, therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Biomarkers
(blood)
- Breast Neoplasms
(blood, drug therapy)
- Dose-Response Relationship, Drug
- Female
- Humans
- Middle Aged
- Prospective Studies
- Tamoxifen
(administration & dosage, therapeutic use)
- Thrombophilia
(drug therapy)
- Tissue Plasminogen Activator
(blood)
- Tretinoin
(administration & dosage, therapeutic use)
|